Since the majority of patients with AML will either not respond or in time develop resistance to venetoclax/azacytidine treatment[24], there is a strong reason to explore the therapeutic efficacy of combination therapies including venetoclax and PI3K/AKT inhibitors alone or in combination with standard AML chemotherapy/HMAs. This evidence concerns the gene AKT1 and acute myeloid leukemia.